Why Are Billionaire Investors Backing Medical Cannabis?
Cannabis is one of the fastest-growing industries across the world. As the legal status of cannabis spreads throughout the globe, the sector has experienced huge growth in 2021 and is set to grow even bigger this year.
Game changing companies like this make sense

CRNX Insider Trading (Crinetics Pharmaceuticals)

Insider Ownership Percentage: 7.10%
Insider Buying (Last 12 Months): $12,600.00
Insider Selling (Last 12 Months): $9,152,743.20

Crinetics Pharmaceuticals Insider Trading History Chart

Crinetics Pharmaceuticals Share Price & Price History

▼ -0.27 (-1.87%)
As of 03/5/2021 12:01 PM ET
Days: 30 | 90 | 365
Cannabis Super Strain Could Destroy Competitors
Its breakthrough super strain of hemp could lead an Oregon agribusiness to blow up the North American cannabis market. That’s good news for people who can move now to become one of the company’s earliest investors. The new super strain of hemp has 3X more CBD per bud than competitors’. The Oregon grower has cracked the cannabis yield code.
Discover What Could Be 2021’s #1 Cannabis Stock

Crinetics Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2020Richard Scott StruthersCEOBuy1,000$12.60$12,600.004,000  
7/15/2020Richard Scott StruthersCEOSell17,500$15.30$267,750.00  
4/17/2020Vivo Capital Viii, LlcMajor ShareholderSell84,598$15.40$1,302,809.20  
4/15/2020Vivo Capital Viii, LlcMajor ShareholderSell215,810$15.50$3,345,055.00  
4/7/2020Vivo Capital Viii, LlcMajor ShareholderSell6,115$14.20$86,833.00  
4/3/2020Vivo Capital Viii, LlcMajor ShareholderSell300,000$13.80$4,140,000.00  
3/9/2020Vivo Capital Viii, LlcMajor ShareholderSell528$19.50$10,296.00  
2/10/2020Vivo Capital Viii, LlcMajor ShareholderSell7,555$21.40$161,677.00  
2/7/2020Vivo Capital Viii, LlcMajor ShareholderSell5,905$22.00$129,910.00  
2/4/2020Vivo Capital Viii, LlcMajor ShareholderSell13,460$22.80$306,888.00  
1/31/2020Vivo Capital Viii, LlcMajor ShareholderSell5,400$21.70$117,180.00  
1/29/2020Vivo Capital Viii, LlcMajor ShareholderSell13,920$22.20$309,024.00  
12/16/2019Matthew K FustDirectorSell3,500$22.50$78,750.0016,036  
6/21/2019Ventures Iv L.P. 5AmInsiderSell250,000$22.20$5,550,000.00  
3/20/2019Vivo Capital Fund Viii, L.P.Major ShareholderSell417,000$22.25$9,278,250.00  
3/18/2019Ventures Iv L.P. 5AmMajor ShareholderSell154,839$24.25$3,754,845.75  
1/22/2019Ventures Iv L.P. 5AmMajor ShareholderSell262,153$21.88$5,735,907.64  
7/20/2018Alan Seth KrasnerInsiderBuy2,000$17.00$34,000.00  
7/20/2018Life Sciences Maste PerceptiveDirectorBuy400,000$17.00$6,800,000.00  
7/20/2018Vivo Capital Viii, LlcMajor ShareholderBuy353,180$18.62$6,576,211.60  
See Full Table

SEC Filings (Institutional Ownership Changes) for Crinetics Pharmaceuticals (NASDAQ:CRNX)

92.15% of Crinetics Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Crinetics Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
3/1/2021UBS Asset Management Americas Inc.14,503$0.21M0.0%+38.1%0.044%
2/25/2021Dimensional Fund Advisors LP23,895$0.34M0.0%N/A0.073%
2/19/2021JPMorgan Chase & Co.79,008$1.11M0.0%+683.3%0.240%
2/16/2021Walleye Capital LLC12,100$0.17M0.0%N/A0.037%
2/16/2021Squarepoint Ops LLC15,406$0.22M0.0%N/A0.047%
2/16/2021Baker BROS. Advisors LP616,520$8.70M0.0%+103.9%1.873%
2/16/2021Nuveen Asset Management LLC137,162$1.94M0.0%-23.7%0.417%
2/16/2021Price T Rowe Associates Inc. MD80,902$1.14M0.0%-6.0%0.246%
2/16/2021Charles Schwab Investment Management Inc.150,723$2.13M0.0%+2.6%0.458%
2/12/2021The Manufacturers Life Insurance Company 17,243$0.24M0.0%+5.1%0.052%
2/12/2021Credit Suisse AG18,470$0.26M0.0%N/A0.056%
2/12/2021Virtus ETF Advisers LLC21,487$0.30M0.1%+10.9%0.065%
2/11/2021Northern Trust Corp317,536$4.48M0.0%-2.5%0.965%
2/11/2021Barclays PLC10,908$0.15M0.0%-23.4%0.033%
2/11/2021Citigroup Inc.10,261$0.15M0.0%+104.9%0.031%
2/10/2021Rhumbline Advisers30,767$0.43M0.0%+9.9%0.093%
2/10/2021Renaissance Technologies LLC25,500$0.36M0.0%N/A0.077%
2/9/2021Wells Fargo & Company MN23,193$0.33M0.0%+16.9%0.070%
2/9/2021Bank of New York Mellon Corp272,637$3.85M0.0%+53.8%0.828%
2/9/2021ProShare Advisors LLC11,075$0.16M0.0%N/A0.034%
2/8/2021Alliancebernstein L.P.27,900$0.39M0.0%+7.7%0.085%
2/5/2021BlackRock Inc.2,113,195$29.82M0.0%+17.5%6.419%
2/4/2021State of Wisconsin Investment Board38,600$0.55M0.0%-11.1%0.117%
2/1/2021Victory Capital Management Inc.52,438$0.74M0.0%-15.0%0.159%
11/16/2020Point72 Asset Management L.P.511,988$8.02M0.0%+29.7%1.555%
11/13/2020Morgan Stanley40,706$0.64M0.0%-81.0%0.124%
11/13/2020Vivo Capital LLC2,263,770$35.47M2.1%-2.3%6.876%
11/13/2020Charles Schwab Investment Management Inc.146,871$2.30M0.0%+8.8%0.446%
11/13/2020UBS Asset Management Americas Inc.10,503$0.17M0.0%-68.4%0.032%
11/13/2020Virtus ETF Advisers LLC19,371$0.30M0.2%-12.1%0.059%
11/12/2020JPMorgan Chase & Co.10,087$0.15M0.0%+10.4%0.031%
11/10/2020State Street Corp443,775$6.95M0.0%+5.9%1.350%
11/9/2020Caas Capital Management LP35,792$0.56M0.0%-69.5%0.109%
11/9/2020Victory Capital Management Inc.61,678$0.97M0.0%-3.3%0.188%
11/6/2020BlackRock Inc.1,798,698$28.19M0.0%+1.7%5.470%
11/6/2020Aperio Group LLC10,910$0.17M0.0%N/A0.033%
11/5/2020California Public Employees Retirement System61,048$0.96M0.0%+11.4%0.186%
11/5/2020Alps Advisors Inc.41,934$0.66M0.0%-6.4%0.128%
11/4/2020Alps Advisors Inc.41,934$0.66M0.0%-6.4%0.128%
10/30/2020BNP Paribas Arbitrage SA6,580$0.10M0.0%+334.0%0.020%
10/16/2020Sanders Morris Harris LLC18,600$0.31M0.1%N/A0.057%
9/15/2020Two Sigma Advisers LP11,800$0.21M0.0%N/A0.036%
8/25/2020Nuveen Asset Management LLC156,572$2.74M0.0%+458.2%0.476%
8/20/2020Charles Schwab Investment Management Inc.134,974$2.37M0.0%+156.0%0.410%
8/17/2020California State Teachers Retirement System40,798$0.72M0.0%+137.2%0.124%
8/17/2020Great West Life Assurance Co. Can2,292$40K0.0%+403.7%0.007%
8/17/2020Jane Street Group LLC18,194$0.32M0.0%N/A0.055%
8/17/2020Perceptive Advisors LLC3,659,381$59.17M1.0%+41.4%11.128%
8/14/2020Orbimed Advisors LLC2,753,567$48.24M0.7%+35.0%8.374%
8/14/2020Opaleye Management Inc.435,200$7.63M1.5%+18.0%1.323%
8/14/2020Point72 Asset Management L.P.394,832$6.92M0.0%N/A1.201%
8/14/2020Bank of America Corp DE20,834$0.37M0.0%+120.8%0.063%
8/14/2020Driehaus Capital Management LLC886,762$15.54M0.4%N/A2.697%
8/13/2020FMR LLC4,926,835$86.32M0.0%+43.3%14.984%
8/13/2020Athanor Capital LP16,364$0.29M0.0%N/A0.050%
8/12/2020Bank of Montreal Can2,156$34K0.0%N/A0.007%
8/12/2020American International Group Inc.16,549$0.29M0.0%+153.2%0.050%
8/12/2020Goldman Sachs Group Inc.14,043$0.25M0.0%N/A0.043%
8/12/2020Bank of New York Mellon Corp185,623$3.25M0.0%+415.2%0.565%
8/12/2020California Public Employees Retirement System54,800$0.96M0.0%+186.9%0.167%
8/7/2020New York State Common Retirement Fund24,800$0.43M0.0%+95.3%0.075%
8/5/2020Alps Advisors Inc.44,809$0.79M0.0%+1.7%0.136%
8/5/2020Ameritas Investment Partners Inc.2,390$42K0.0%+151.1%0.007%
8/5/20205AM Venture Management LLC1,362,286$23.87M5.2%-26.8%4.147%
8/5/2020Virtus ETF Advisers LLC22,026$0.39M0.2%N/A0.067%
8/5/2020Russell Investments Group Ltd.5,600$98K0.0%N/A0.017%
8/5/2020Swiss National Bank36,200$0.63M0.0%+92.6%0.110%
7/31/2020UBS Group AG9,093$0.16M0.0%+10.7%0.028%
7/31/2020Bpifrance SA12,418$0.22M0.1%N/A0.038%
7/27/2020Jacobi Capital Management LLC414$53K0.0%-86.2%0.001%
7/22/2020Hershey Trust Co.19,778$0.35M0.0%+583.2%0.060%
7/20/2020Versant Venture Management LLC2,030,616$35.58M5.1%N/A6.182%
7/20/2020SG Americas Securities LLC14,802$0.26M0.0%N/A0.045%
6/19/2020State Street Corp224,494$3.30M0.0%-0.9%0.683%
5/18/2020Vivo Capital LLC3,320,801$48.82M4.4%N/A10.109%
5/15/2020RA Capital Management L.P.1,961,209$28.83M0.9%+4.6%5.971%
5/15/2020Morgan Stanley2,251$34K0.0%-87.1%0.007%
5/14/2020Wells Fargo & Company MN6,759$99K0.0%-27.1%0.021%
5/14/2020Geode Capital Management LLC134,019$1.97M0.0%+4.4%0.408%
5/14/2020Janus Henderson Group PLC491,691$7.23M0.0%+0.6%1.497%
5/14/2020Burrage Capital Management LLC282,272$4.02M4.0%+37.2%0.859%
5/14/2020Alliancebernstein L.P.14,800$0.22M0.0%+25.4%0.045%
5/13/2020BNP Paribas Arbitrage SA3,447$51K0.0%+112.3%0.010%
5/12/2020Citigroup Inc.3,217$47K0.0%+42.9%0.010%
5/12/2020Victory Capital Management Inc.184,724$2.72M0.0%-5.4%0.587%
5/11/2020State Street Corp224,494$3.30M0.0%-0.9%0.714%
5/8/2020Swiss National Bank18,800$0.28M0.0%+5.0%0.077%
5/6/2020Alps Advisors Inc.44,040$0.65M0.0%-10.4%0.179%
5/4/2020Victory Capital Management Inc.184,724$2.72M0.0%-5.4%0.752%
5/1/2020BlackRock Inc.722,303$10.62M0.0%-1.3%2.940%
5/1/2020UBS Group AG8,216$0.12M0.0%-51.9%0.033%
4/29/20205AM Venture Management LLC1,862,286$27.38M8.5%-21.2%7.580%
4/20/2020Hershey Trust Co.2,895$43K0.0%-57.1%0.012%
2/20/2020Geode Capital Management LLC128,409$3.22M0.0%+5.5%0.530%
2/18/2020Alliancebernstein L.P.11,800$0.30M0.0%+5.4%0.049%
2/18/2020Janus Henderson Group PLC488,872$12.27M0.0%-1.6%2.018%
2/14/2020Point72 Asset Management L.P.33,865$0.85M0.0%-74.3%0.140%
2/14/2020Cubist Systematic Strategies LLC4,700$0.12M0.0%+164.3%0.019%
2/14/2020Bank of America Corp DE12,998$0.33M0.0%+14.9%0.054%
2/14/2020Bank of New York Mellon Corp35,847$0.90M0.0%+3.4%0.148%
Data available starting January 2016

See Full Table
Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $14.18

50 Day Range

MA: $15.44

52 Week Range

Now: $14.18


3,796 shs

Average Volume

124,844 shs

Market Capitalization

$466.83 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' top insider investors include:
  1. Matthew K Fust (Director)
  2. Richard Scott Struthers (CEO)
  3. Ventures Iv LP 5Am (Insider)
  4. Ventures Iv LP 5Am (Major Shareholder)
  5. Vivo Capital Fund Viii, LP (Major Shareholder)
  6. Vivo Capital Viii, Llc (Major Shareholder)

Who are the major institutional investors of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' top institutional investors include:
  1. BlackRock Inc. — 6.42%
  2. Baker BROS. Advisors LP — 1.87%
  3. Northern Trust Corp — 0.96%
  4. Bank of New York Mellon Corp — 0.83%
  5. Charles Schwab Investment Management Inc. — 0.46%
  6. Nuveen Asset Management LLC — 0.42%

Which institutional investors are selling Crinetics Pharmaceuticals stock?

During the previous quarter, CRNX stock was sold by these institutional investors:
  1. Nuveen Asset Management LLC
  2. Victory Capital Management Inc.
  3. Northern Trust Corp
  4. Price T Rowe Associates Inc. MD
  5. State of Wisconsin Investment Board
  6. Barclays PLC
During the last year, company insiders that have sold Crinetics Pharmaceuticals company stock include:
  1. Matthew K Fust (Director)
  2. Richard Scott Struthers (CEO)

Which institutional investors are buying Crinetics Pharmaceuticals stock?

In the last quarter, CRNX stock was bought by institutional investors including:
  1. BlackRock Inc.
  2. Baker BROS. Advisors LP
  3. Bank of New York Mellon Corp
  4. JPMorgan Chase & Co.
  5. Renaissance Technologies LLC
  6. Dimensional Fund Advisors LP
  7. Credit Suisse AG
  8. Squarepoint Ops LLC
Biotech Opens with a Big Bang
This biotech stock be the next unicorn with its disruptive technologies for mental health
Read full story here